Exercise during curative chemotherapy for breast cancer has proven benefits. It helps reduce fatigue, preserve muscle strength, improve fitness, and enhance overall quality of life. Staying physically active…
With a wave of FDA approvals and promising clinical trials, treatment options for metastatic breast cancer are expanding fast. Amy Tiersten, MD, highlights the power of immunotherapies—especially checkpoint…
NEW YORK (Reuters Health) – The 20-year survival rate for people diagnosed with thin or T1 melanomas 1 mm thick or less, the most common type, is 96%,…
NEW YORK (Reuters Health) – When patients with advanced gastric cancer have not benefitted from one or two chemotherapy regimens for metastatic disease, salvage chemotherapy improves their overall…
NEW YORK (Reuters Health) – Two independent studies have shown that reduced-activity variants of the cytochrome P450 2D6 (CYP2D6) enzyme are not associated with poorer disease control in…
NEW YORK (Reuters Health) – The success of radiofrequency ablation (RFA) for small renal tumors is strongly dependent on tumor size, according to a study in the April…
NEW YORK (Reuters Health) – The reduced risk of developing invasive breast cancer with adjuvant tamoxifen therapy after lumpectomy and radiation for ductal carcinoma in situ (DCIS) is…
NEW YORK (Reuters Health) – The selective inhibitor of Janus kinase (JAK) 1 and 2, ruxolitinib, significantly reduces spleen size and other debilitating symptoms in patients with myelofibrosis…
NEW YORK (Reuters Health) – Lung cancer patients undergoing chemotherapy can be treated safely with erythropoiesis-stimulating agents (ESAs), according to findings published in the 24 January online issue…
NEW YORK (Reuters Health) – Men 60 years old and younger have excellent quality-of-life outcomes after proton therapy for prostate cancer, according to findings published in the January…
NEW YORK (Reuters Health) – Stereotactic body radiotherapy (SBRT) may be an effective alternative to surgery for solitary pulmonary nodules clinically diagnosed as lung cancer, researchers from Japan…
NEW YORK (Reuters Health) – Adding the multitargeted tyrosine kinase inhibitor sunitinib (Sutent; Pfizer) to docetaxel did not improve clinical outcomes when used in the first-line setting in…
